[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Cuibai Wei，Clinical Professor\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":90},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100583093","the-clinical-study-of-synaptic-plasticity-based-lencanumab-for-the-treatment-of-early-alzheimers-disease-100583093",false,"NCT06871839","The Clinical Study of Synaptic Plasticity-based Lencanumab for the Treatment of Early Alzheimer's Disease","Inclusion Criteria:\n\n1. Age between 50 and 90 years.\n2. Male or female patients.\n3. Patients with MCI and mild AD.\n4. MMSE score ≥20, CDR overall score of 0.5 or 1.\n5. Amyloid-positive confirmed by Amyloid-PET or CSF.\n6. Have a reliable caregiver to accompany the patient during study visits and supervise the use of study medication during the trial.\n7. Agree to participate in the study and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with cognitive impairment due to reasons other than AD.\n2. A history of transient ischemic attack (TIA), stroke, cerebral hemorrhage, or seizure within the 12 months prior to screening.\n3. A score of \\>17 on the Hamilton Depression Scale at screening, or any suicidal behavior within 6 months prior to screening, at screening, or at the baseline visit, as well as any psychiatric diagnosis or symptoms that interfere with the study procedure (such as hallucinations, anxiety disorder, or paranoia).\n4. Patients with a bleeding disorder or receiving anticoagulant therapy, as well as any with malignant tumors, severe gastrointestinal, kidney, liver, respiratory, immune, endocrine, and cardiovascular system diseases that affect this study.\n5. A hypersensitivity reaction to ranucimab or any other ingredient in the injection solution, or to any monoclonal antibody treatment.\n6. Contraindications to MRI scanning, including those with a pacemaker\u002Fdefibrillator or ferromagnetic metal implants (except for skull and cardiac devices approved as safe for MRI scanning).\n7. A known or suspected history of drug or alcohol abuse or dependence within the 2 years prior to screening.\n8. Participation in a clinical study involving any therapeutic monoclonal antibody or novel compounds for the treatment of AD within the 6 months prior to screening, unless it can be proven that the subject was in the placebo treatment group.\n9. Planning to undergo surgery requiring general anesthesia during the study period.\n10. A positive pregnancy test result, lactation, or pregnancy in females at screening or baseline.","ALL","50 Years","90 Years",{"count":19,"type":20},120,"ESTIMATED","OBSERVATIONAL","Alzheimer's disease (AD) manifests itself in cognitive decline, impaired ability to perform daily life, and a variety of behavioral and psychiatric symptoms, seriously endangering the health of the elderly. The prevalence and disability rates of AD in China remain high, and the lack of effective treatment options has brought a heavy burden to patients and their families. Early intervention is regarded as an effective strategy to improve clinical symptoms, delay disease progression and maintain current quality of life. The humanized monoclonal antibody lencanemab (Lecanemab) was approved by the U.S. FDA in July 2023 for the treatment of mild cognitive impairment or mild dementia caused by AD, and was officially approved in January 2024 in China. Lencanemab highly targets soluble and insoluble neurotoxic β-amyloid (Aβ) proteins, reducing pathogenic Aβ plaque deposition and preventing its formation in the brains of AD patients, thus reducing neurotoxicity and improving patients' cognitive functions. In addition, lencanumab may also play a neuroprotective role by modulating synaptic plasticity and regulating neural network activity in brain neurons. However, there is a lack of clinical studies to prove this mechanism. In this study, we will enroll consecutive patients with early AD treated with lencanemab infusion as well as those receiving conventional anti-dementia therapy, and comprehensively assess the effects and intrinsic molecular mechanisms of lencanemab on synaptic function and neural networks using magnetic resonance imaging, molecular imaging positron emission tomography (PET), neuropsychological assessment, and analysis of blood cerebrospinal fluid samples.",[24,25,26],"Alzheimer's Disease","Lecanemab","Functional Magnetic Resonance Imaging",[28,25,29],"Alzheimer's disease","functional magnetic resonance imaging","RECRUITING","2025-07-19",{"date":33,"type":34},"2025-07-22","ACTUAL",{"date":36,"type":34},"2025-03-10",{"date":38,"type":20},"2026-12-31",{"name":40,"class":41},"Cuibai Wei，Clinical Professor","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":15,"minAge":16,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":42},"100492856","exploring-the-predicting-biomarkers-from-mild-cognitive-impairment-to-dementia-ebmid-100492856","NCT05697588","Exploring the Predicting Biomarkers From Mild Cognitive Impairment to Dementia (EBMID)","Studies on Biomarkers for Mild Cognitive Impairment Conversion to Dementia","Inclusion Criteria:\n\n* Male or female patients aged ≥50 and ≤85 years;\n\n  * Meet the diagnostic criteria for dementia or MCI; ③ Neuropsychological score: MMSE 15-28 points, CDR≤1 point; ④ The patients and their families were informed and signed the informed consent.\n\nExclusion Criteria:\n\n* There are other neurological diseases that can cause brain dysfunction (such as depression, brain tumors, Parkinson's disease disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, traumatic brain injury, normal intracranial pressure hydrocephalus, etc.);\n\n  * There are other systemic diseases that can cause cognitive impairment (such as hepatic insufficiency, renal insufficiency, Thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.);\n\n    * Suffering from a disease that cannot cooperate with the completion of cognitive examination; ④ There are contraindications to nuclear magnetic resonance;\n\n      * There is mental and neurodevelopmental delay; ⑥ refuse to draw blood; ⑦ Refuse to sign the informed consent.",true,"85 Years",{"count":53,"type":20},900,"Mild cognitive impairment (MCI) represents a transitional stage between healthy aging and dementia, and affects more than 15% of the population over the age of 60 in China. About 15% patients with MCI could progress into dementia after two years and about one-third develop into dementia within five years, which will lead to suffering, as well as staggering economic and care burden. So, exploring the predicting biomarkers from MCI to dementia to identify and delay progression to dementia at an early stage is of great social and clinical significance. Some reports based on a single neural biomarker suggest that risk models can predict the conversion of MCI to dementia, but no widely recognized prediction models basing on multiple complex markers have been used in clinical practice. The objectives of this study are to outline the spectrum of MCI transforming into dementia through a 5-year prospective longitudinal cohort study; Secondly, screening biomarkers for MCI transmit to dementia are based on clinical symptoms, neuropsychology, neuroimaging, neuroelectrophysiology, and humoral markers tests data.",[56,57],"Biomarkers","MCI Conversion to Dementia","2025-07-18",{"date":60,"type":34},"2025-07-24",{"date":62,"type":34},"2023-02-28",{"date":64,"type":20},"2028-02-28",{"name":40,"class":41},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":50,"sex":15,"minAge":73,"maxAge":17,"enrollmentInfo":74,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":42},"100548292","exploring-the-diagnostic-biomarkers-of-cognitive-disorders-in-china-100548292","NCT06419101","Exploring the Diagnostic Biomarkers of Cognitive Disorders in China","Cohort Study on Biomarkers of Cognitive Disorders in China","Inclusion Criteria:\n\n* Male or female patients aged ≥40 and ≤90years;\n* Chief complaint or others describe a cognitive decline;\n* Ability to communicate in Chinese;\n* The patients and their families were informed and signed the informed consent.\n\nExclusion Criteria:\n\n* MMSE\\\u003C10;\n* There are other neurological diseases that can cause brain dysfunction (such as depression, brain tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, traumatic brain injury, normal intracranial pressure hydrocephalus, etc.);\n* There are other systemic diseases that can cause cognitive impairment (such as hepatic insufficiency, renal insufficiency, Thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.);\n* Suffering from a disease that cannot cooperate with the completion of cognitive examination;\n* There are contraindications to nuclear magnetic resonance;\n* There is mental and neurodevelopmental delay;\n* Refuse to draw blood;\n* Refuse to sign the informed consent.","40 Years",{"count":75,"type":20},3000,"Dementia is a syndrome characterized by progressive global cognitive impairment that impairs occupational, family, or social functioning. It detrimentally affects personal health and quality of life, imposing significant medical economy, social and psychological burden on the countries and the patients' family. The internationally renowned dementia cohort includes the DIAN that focused on genetics studies, the ADNI cohort featuring imaging and the FINGERS cohort focused on risk factor intervention, etc. Establishing standardized and shared longitudinal follow-up dementia cohorts and clinical database is an essential challenge for constructing dementia cohort in China. Moreover, there is a lack of large-scale prospective longitudinal follow-up cohorts within the Chinese population that cover subjective cognitive decline (SCD) to explore biomarkers with diagnostic and early warning value for different kinds of dementia and pre-dementia stages. The study will rely on the dementia cohort based on Chinese population to explore the biological phenotype characteristics of the pre-dementia stage and different dementia subtypes, and observe the dynamic change rules of the dementia cohort vertically, so as to foster early intervention and improve prognosis for individuals with dementia.",[56,78],"Dementia",[80,81],"dementia","diagnostic biomarkers","2024-11-12",{"date":84,"type":34},"2024-11-14",{"date":86,"type":34},"2024-05-30",{"date":88,"type":20},"2035-05-10",{"name":40,"class":41},""]